# Qingsong Capital

> Qingsong Capital is a VC fund in Beijing backing Biotechnology and Medical. See 35 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 35
- Last investment: Jul 2026
- Lead investor: 29%
- Last updated: Aug 2026
- Website: https://www.ctsfunds.com/

Qingsong Capital is an entrepreneurial private equity investment institution focusing on the investments in the field of biotechnology and medical health.

## Contacts

5 contacts available for Qingsong Capital. Shizune tracks 2 team members at Qingsong Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/qingsong-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 15 | 43% |
| Medical | 13 | 37% |
| Health Care | 10 | 29% |
| Manufacturing | 6 | 17% |
| Pharmaceutical | 5 | 14% |

28 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 10 | 29% |
| Seed | 4 | 11% |
| Series B | 4 | 11% |
| Venture - Series Unknown | 4 | 11% |
| Angel | 3 | 9% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 23 | 66% |
| Hong Kong | 1 | 3% |
| United States | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Li Jing | Executive Director | 3 | https://shizune.co/investors/profile/li-jing-fce9 |
| Zhang Song | Founding Partner | 1 | https://shizune.co/investors/profile/zhang-song |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rushen Robotics | Rushen Robotics focuses on the domains of rehabilitation and fitness, and is committed to building modular and human-machine integrated rehabilitation robots. | $14.7M | Seed | Jul 03, 2026 |  |
| Gestala | Gestala is China’s first pioneer in ultrasound-based Brain-Computer Interface (BCI). We are dedicated to engineering a platform with full-brain read-write capabilities, offering transformative therapeutic modalities for neurological disorders. Beyond clinical impact, we aim to decode the neural code and pave the way for a symbiotic future wherebrain science and artificial intelligence converge. | $61.9M | Angel | Jul 03, 2026 |  |
| Xellar Biosystems | Xellar Biosystems is a wet artificial intelligence biotechnology company that provides analysis of drug testing and treatment. | $29.5M | Series A | Jun 30, 2026 |  |
| Gestala | Gestala is China’s first pioneer in ultrasound-based Brain-Computer Interface (BCI). We are dedicated to engineering a platform with full-brain read-write capabilities, offering transformative therapeutic modalities for neurological disorders. Beyond clinical impact, we aim to decode the neural code and pave the way for a symbiotic future wherebrain science and artificial intelligence converge. | $21.8M | Angel | Mar 12, 2026 |  |
| Danyuan Medical | Danyuan Medical is a high-tech enterprise focused on the research, development, and innovation of advanced cardiac rhythm management medical devices. The company integrates cutting-edge biomedical engineering, clinical expertise, and precision manufacturing to design reliable solutions for diagnosing and treating heart rhythm disorders. |  | Series A | Feb 26, 2026 |  |
| Aerotech | Aerotech specialized manufacturer of R&D and production of gas pipe valves. It is a service supplier of high-end products and semiconductor electropolishing technology core solutions. |  | Series B | Jan 05, 2026 |  |
| Worg Pharmaceuticals | Worg Pharmaceuticals is a clinical stage biopharmaceutical company developing new treatments for allergy and other diseases. | $42.6M | Series D | Dec 22, 2025 |  |
| Yili Pharmaceutical | Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development. | $14M | Angel | Sep 25, 2025 |  |
| United Imaging Intelligence | United Imaging Intelligence provides full-stack and full-spectrum intelligent solutions covering all diseases. | $139.3M | Series A | Jun 20, 2025 |  |
| Suzhou Meichuang | Meichuang Medical is an innovative medical device company that focuses on the R&D, manufacturing and commercialization of high-end medical devices in the fields of peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance | $13.6M | Series A | Jan 15, 2025 |  |

10 of 35 investments shown.

## Co-investors
- [CTS Capital](https://shizune.co/investors/profile/cts-capital) — VC Fund, 5 deals together
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 4 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 4 deals together
- [BOHE Angel Fund](https://shizune.co/investors/profile/bohe-angel-fund) — VC Fund, 3 deals together
- [Qingsong Fund](https://shizune.co/investors/profile/qingsong-fund) — VC Fund, 3 deals together
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Life Science Investors in China](https://shizune.co/investors/life-science-investors-china)
- [Life Science VC Funds in China](https://shizune.co/investors/life-science-vc-funds-china)

## FAQ

### What does Qingsong Capital invest in?

Qingsong Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 35 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Qingsong Capital?

Public channels for Qingsong Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Qingsong Capital?

The team at Qingsong Capital includes Li Jing (Executive Director) and Zhang Song (Founding Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co